S. 3566, Recalcitrant Cancer Research Act of 2012

Cost Estimate
September 20, 2012

As ordered reported by the Senate Committee on Health, Education, Labor, and Pensions on September 19, 2012

S. 3566 would require the Director of the National Institutes of Health (NIH) to develop a scientific framework to conduct and support research on recalcitrant cancers—cancers with a five-year survival rate of less than 50 percent. As part of the scientific framework, research would be coordinated across working groups, recommendations would be made to advance research, and assessments on the progress in improved outcomes for people suffering from recalcitrant cancers would be conducted for each recalcitrant cancer identified.

The bill would impose additional reporting requirements for each type of recalcitrant cancer. However, CBO estimates that no significant additional resources would be needed to meet those reporting requirements during the 2013-2017 period because the activities specified in the bill are generally consistent with activities that NIH already performs under current law. Thus, CBO estimates that implementing S. 3566 would have no significant budgetary effect during the 2013-2017 period.

Enacting the bill would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.

S. 3566 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would not affect the budgets of state, local, or tribal governments.